GHIT Fund Progress Hailed But Much To Do
This article was originally published in PharmAsia News
The Japan-based GHIT Fund was set up just over two years ago to accelerate the development of drugs, vaccines and diagnostics for malaria, tuberculosis and other neglected infectious diseases affecting developing countries by building on Japan's science and research capabilities. While good progress has been made, political support and a sense of urgency are required to ensure continued impact.
You may also be interested in...
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.